Dysmenorrhea Treatment Market Research Reportβ€”Global Forecast till 2027

Dysmenorrhea Treatment Market: Information by Product Type (Primary Dysmenorrhea and Secondary Dysnmenorrhea), by Type of Treatment (Pain Relievers, Hormonal Therapy, Surgery), by End User (Hospitals & Clinics, Research Centers), and by Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)β€”Forecast till 2027

ID: MRFR/HC/0256-CR | December 2021 | Region: Global | 111 Pages         

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF DYSMENORRHEA AMONG ADOLESCENT GIRLS

4.2.2 INCREASING CASES OF MENSTRUAL CRAMPS DUE TO GENETIC DISORDERS

4.3 RESTRAINTS

4.3.1 CONCERNS PERTAINING TO SIDE EFFECTS

4.3.2 HIGH AVAILABILITY OF ALTERNATIVE PRODUCTS

4.4 OPPORTUNITIES

4.4.1 THE EMERGENCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR DYSMENORRHEA TREATMENT

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 COVID-19 IMPACT ANALYSIS

5.3.1 IMPACT ON WOMEN'S HEALTH

5.3.2 IMPACT ON TREATMENT

6 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE

6.1 OVERVIEW

6.2 PRIMARY DYSMENORRHEA

6.3 SECONDARY DYSMENORRHEA

7 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT

7.1 OVERVIEW

7.2 PAIN RELIEVERS

7.3 HORMONAL THERAPY

7.4 SURGERY

7.5 OTHERS

8 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS & CLINICS

8.3 RESEARCH CENTRES

8.4 OTHERS

9 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY REGION

9.1 INTRODUCTION

9.2 AMERICAS

9.2.1 NORTH AMERICA

9.2.1.1 US

9.2.1.2 CANADA

9.2.2 LATIN AMERICA

9.3 EUROPE

9.3.1 WESTERN EUROPE

9.3.1.1 GERMANY

9.3.1.2 FRANCE

9.3.1.3 UK

9.3.1.4 ITALY

9.3.1.5 SPAIN

9.3.1.6 REST OF WESTERN EUROPE

9.3.2 EASTERN EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 JAPAN

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 MIDDLE EAST & AFRICA

9.5.1 MIDDLE EAST

9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 MERGER/ACQUISITION

10.7 FINANCIAL MATRIX

10.7.1 SALES (USD MILLION), 2020

10.7.2 R&D EXPENDITURE (USD MILLION), 2020

11 COMPANY PROFILES

11.1 NOVARTIS AG

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/SERVICES OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 PFIZER, INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS/SERVICES OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 RECKITT BENCKISER GROUP PLC.

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS/SERVICES OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 SANOFI S.A.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS/SERVICES OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 VIATRIS INC.

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS/SERVICES OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 JOHNSON & JOHNSON SERVICES INC.

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS/SERVICES OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 GLAXOSMITHKLINE PLC

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS/SERVICES OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 F. HOFFMANN-LA ROCHE LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS/SERVICES OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 BAYER AG

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS/SERVICES OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 SWOT ANALYSIS

11.9.6 KEY STRATEGIES

11.10 FOCUS CONSUMER HEALTHCARE, LLC

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS/SERVICES OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

 

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS USED DURING MENSTRUATION IN THE TREATMENT OF PRIMARY DYSMENORRHEA IN ADOLESCENTS AND YOUNG ADULTS

TABLE 3 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR PRIMARY DYSMENORRHEA, BY REGION, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR SECONDARY DYSMENORRHEA, BY REGION, 2018–2027 (USD MILLION)

TABLE 6 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 7 GLOBAL: DYSMENORRHEA TREATMENT MARKET FOR PAIN RELIEVERS, BY REGION, 2018–2027 (USD MILLION)

TABLE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR HORMONAL THERAPY, BY REGION, 2018–2027 (USD MILLION)

TABLE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR SURGERY, BY REGION, 2018–2027 (USD MILLION)

TABLE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)

TABLE 11 GLOBAL DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 12 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2018–2027 (USD MILLION)

TABLE 13 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR RESEARCH CENTRES, BY REGION, 2018–2027 (USD MILLION)

TABLE 14 GLOBAL DYSMENORRHEA TREATMENT MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)

TABLE 15 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 16 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 17 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 18 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 19 AMERICAS: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 20 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 21 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 22 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 23 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 24 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 25 US: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 26 US: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 27 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 28 CANADA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 29 CANADA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 30 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 31 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 32 LATIN AMERICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 33 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY REGION, 2018–2027 (USD MILLION)

TABLE 34 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 35 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 36 EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 37 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 38 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 39 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 40 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 41 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 42 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 43 GERMANY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 44 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 45 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 46 FRANCE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 47 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 48 UK: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 49 UK: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 50 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 51 ITALY: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 52 ITALY: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 53 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 54 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 55 SPAIN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 56 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 57 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 58 REST OF WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 59 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 60 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 61 EASTERN EUROPE: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 62 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 63 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 64 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 65 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 66 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 67 CHINA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 68 CHINA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 69 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 70 INDIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 71 INDIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 72 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 73 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 74 JAPAN: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 75 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 76 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 77 AUSTRALIA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 78 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 79 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 80 SOUTH KOREA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 81 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 82 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 83 REST OF ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 84 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 85 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 86 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 87 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 88 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 89 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 90 MIDDLE EAST: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 91 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2018–2027 (USD MILLION)

TABLE 92 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2018–2027 (USD MILLION)

TABLE 93 AFRICA: DYSMENORRHEA TREATMENT MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 94 MAJOR PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

TABLE 95 MOST ACTIVE PLAYER IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

TABLE 96 MERGER/ACQUISITION

TABLE 97 NOVARTIS AG: PRODUCTS/SERVICES OFFERED

TABLE 98 PFIZER, INC.: PRODUCTS/SERVICES OFFERED

TABLE 99 RECKITT BENCKISER GROUP PLC.: PRODUCTS/SERVICES OFFERED

TABLE 100 RECKITT BENCKISER GROUP PLC.: KEY DEVELOPMENTS

TABLE 101 SANOFI S.A.: PRODUCTS/SERVICES OFFERED

TABLE 102 SANOFI S.A.: KEY DEVELOPMENTS

TABLE 103 VIATRIS INC.: PRODUCTS/SERVICES OFFERED

TABLE 104 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED

TABLE 105 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED

TABLE 106 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED

TABLE 107 BAYER AG: PRODUCTS/SERVICES OFFERED

TABLE 108 BAYER AG: KEY DEVELOPMENTS

TABLE 109 FOCUS CONSUMER HEALTHCARE, LLC: PRODUCTS/SERVICES OFFERED

 

LIST OF FIGURES

FIGURE 1 GLOBAL DYSMENORRHEA TREATMENT MARKET STRUCTURE

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 3 MARKET DYNAMICS: GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 4 DRIVERS: IMPACT ANALYSIS

FIGURE 5 RESTRAINTS: IMPACT ANALYSIS

FIGURE 6 VALUE CHAIN ANALYSIS OF THE GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 8 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE, 2020 & 2027 (USD MILLION)

FIGURE 9 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2027 (USD MILLION)

FIGURE 10 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY TYPE OF TREATMENT, 2020 & 2027 (USD MILLION)

FIGURE 11 GLOBAL: DYSMENORRHEA TREATMENT MARKET, BY REGION 2020 & 2027 (USD MILLION)

FIGURE 12 GLOBAL: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 13 AMERICAS: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 14 NORTH AMERICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 15 EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY REGION 2020

FIGURE 16 WESTERN EUROPE: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 17 ASIA PACIFIC: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY 2020

FIGURE 18 MIDDLE EAST & AFRICA: DYSMENORRHEA TREATMENT MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DYSMENORRHEA TREATMENT MARKET

FIGURE 21 GLOBAL DYSMENORRHEA TREATMENT MARKET: COMPETITIVE LANDSCAPE

FIGURE 22 SALES (USD MILLION), 2020

FIGURE 23 R&D EXPENDITURE (USD MILLION), 2020

FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 NOVARTIS AG: SWOT ANALYSIS

FIGURE 26 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 PFIZER, INC.: SWOT ANALYSIS

FIGURE 28 RECKITT BENCKISER GROUP PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 RECKITT BENCKISER GROUP PLC.: SWOT ANALYSIS

FIGURE 30 SANOFI S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 SANOFI S.A.: SWOT ANALYSIS

FIGURE 32 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 VIATRIS INC.: SWOT ANALYSIS

FIGURE 34 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS

FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 40 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 BAYER AG: SWOT ANALYSIS

FIGURE 42 FOCUS CONSUMER HEALTHCARE, LLC: SWOT ANALYSIS

Dysmenorrhea Treatment Market

Dysmenorrhea Treatment Market is expected to cross USD 6,312.88 million at a CAGR of 7.9% from 2020-2027

Segmentation

By Product Type Primary Dysmenorrhea Secondary Dysmenorrhea
By Type of Treatment Pain Relievers Hormonal Therapy Surgery
By End User Hospitals And Clinics Research Centers

Key Players

  • Johnson & Johnson (US)
  • GlaxoSmithKline PLC (UK)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Focus Consumer
  • Healthcare LLC (US)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • Reckitt Benckiser Group plc. (UK)
  • Sanofi S.A. (France)

Drivers

  • Increasing prevalence of dysmenorrhea among adolescent girls
  • Increasing cases of menstrual cramps due to genetic disorders
Speak to Analyst Request a Free Sample

Dysmenorrhea Treatment Market Forecast


The global dysmenorrhea treatment market is expected to cross USD 6,312.88 million by 2027 at a CAGR of 7.9%.


Market Overview:


Dysmenorrhea is commonly known as menstrual cramps, which affects women. The key factors attributed to driving the market growth are the increasing prevalence of dysmenorrhea among adolescent girls and rising cases of menstrual cramps due to genetic disorders. However, concerns pertaining to the side effects and high availability of alternative products are projected to curb the growth of the market. Also, the increasing female population across the globe and growing menstrual health awareness is creating opportunities for the dysmenorrhea treatment market.


COVID-19 Analysis:


The outbreak of coronavirus impacted women's health across the globe. The female population affected by COVID-19 continued to face a prolonged state of illness that exaggerated the menstrual cycle duration leading to several health problems. In addition, the working women were under high stress due to the multiple households works and job-related activities during the lockdown. The change in lifestyle and diet affected the menstrual cycle among women. High stress, anxiety delayed the menstrual cycle and also caused variable menstrual cramps. Moreover, the women affected by coronavirus experienced painful periods along with changes in hormone levels and irregularity in the cycle. Such factors drive the dysmenorrhea treatment market and are projected to grow at a decent pace in the predicted time period.


Market Dynamics:


Market Drivers


  • Increasing prevalence of dysmenorrhea among adolescent girls


The female population in developing and underdeveloped countries faces menstrual issues due to limited awareness about treatment, societal pressure, and other factors. International health organizations such as WHO monitor the menstrual health status of women and girls globally. According to UNICEF, there are more than 1.2 billion juveniles aged 10-19 years and contribute 16% of the global population. In addition, more than 50% of the adolescent resides in Asia-Pacific which is one of the fastest growing regional market.



  • Increasing cases of menstrual cramps due to genetic disorders


Market Restraints


  • Concerns pertaining to side effects


Dysmenorrhea treatment offers relief to women suffering from menstrual cramps. However, the consumption of different types of medications and hormonal therapies impact the patient's health negatively. A few of the common side effects reported after the dysmenorrhea treatment include drowsiness, stomach cramps, and an increase in the thickness of lung secretions.



  • High availability of alternative products


Market Opportunities


  • The emergence of nonsteroidal anti-inflammatory drugs for dysmenorrhea treatment


The increasing female population across the globe and increasing menstrual health awareness among young girls is creating opportunities for the dysmenorrhea treatment market. The demand for nonsteroidal anti-inflammatory drugs (NSAIDs) is rising owing to increasing cases of primary dysmenorrhea. The NSAIDs prohibit the production of cyclooxygenase-mediated prostaglandin that is responsible for menstrual pain.


Global Dysmenorrhea Treatment Market Share (%), by Type, 2020
Dysmenorrhea Treatment Market Share by Type 2020
Source: MRFR Analysis


Segment Overview


The global dysmenorrhea treatment market has been divided based on type, type of treatment and end user.


By Type



  • Primary Dysmenorrhea


In primary dysmenorrhea, recurrent and painful menstrual cramps occur just two days before menstrual bleeding. The pain is felt in the back, lower abdomen, or thigh and is mild to severe in nature, and it persists up to 12 to 72 hours. The various symptoms of primary dysmenorrhea include nausea, vomiting, fatigue, and diarrhea.



  • Secondary Dysmenorrhea


According to the published article in the American College of Obstetricians and Gynecologists in 2018, endometriosis is the leading cause of secondary dysmenorrhea in adolescents. Endometriosis should be considered in patients with persistent, clinically significant dysmenorrhea.


By Type of Treatment


On the basis of type of treatment, the market is bifurcated into pain relievers, hormonal therapy, surgery, and others.



  • Pain Relievers


Pain relievers refer to the medications used to relieve the cramping pelvic pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the first-line therapy for primary dysmenorrhea. Naproxen, ibuprofen, and diclofenac are three of the most popular period pain medications sold by different companies under different brand names. While most pain relievers can be bought without a prescription, some require a prescription for purchase.



  • Hormonal Therapy


Hormone therapy products are also called birth control therapies, which suppress ovulation and lower the severity of menstrual cramps. They contain hormones that regulate ovulation and menstrual cycles. Some hormone therapy products include birth control pill, vaginal ring, skin patch, Depo-Provera injection, intrauterine devices (IUDs), and implants, which contain hormones and release them as intended. They can also make periods less painful, lighter, and shorter.



  • Surgery


Surgical mode of treatment are usually used when other treatment options are not proving to be effective or if the patient is suffering from secondary dysmenorrhea. Sometimes, surgical methods such as laparoscopy are used for diagnostic purposes to detect the underlying causes for dysmenorrhea, such as fibroids, endometriosis, adhesions, ovarian cysts, and ectopic pregnancy.



  • Others


Other dysmenorrhea treatment types include regular exercising, abdominal and lower back massage, use of heat packs, dietary supplementation, and restrictions such as avoidance of caffeine, acupuncture and acupressure, yoga, and breathing exercises. According to a global survey from March 2019, done by St Mary’s University (UK) and FitrWoman (UK), of over 14,000 females, 78% of them reported reduced period pain from exercising.


By End User


On the basis of end user, the market is divided into hospitals & clinics, research centers, and others.



  • Hospitals & Clinics


Hospitals & clinics provide expertise and the technology required to correctly diagnose and provide treatments to women suffering from dysmenorrhea. They also help patients with proper consultation and prescriptions for drugs to be taken in safe amounts, especially in the case of secondary dysmenorrhea where proper consultation from medical experts is required, and surgical therapies can be performed efficiently in hospitals, along with the option to patients for an extended stay as well for patients to recuperate after surgery.



  • Research Centers


Research centers extensively research the available treatment options and innovate novel treatments that are more effective and with lesser side effects. Furthermore, research centers study the treatments such as the use of NSAIDs and other medications for their side effects on the users and suggest changes in prescriptions, if required in the FDA post-approval monitoring processes. Research centers also provide support to drug companies in their drug development stages and in product approvals.



  • Others


Other end users include ambulatory surgical centers and specialty centers. Ambulatory surgical centers provide same-day surgical procedures for patients suffering from dysmenorrhea. Many surgical methods such as laparoscopy, and hysteroscopy can be performed within the same day in ambulatory surgical centers.


Global Dysmenorrhea Treatment Market Share (%), by Region, 2020
Dysmenorrhea Treatment Market Share by Region 2020
Source: MRFR Analysis


Regional Analysis


The global dysmenorrhea treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Americas:


The Americas accounted for the largest share in the dysmenorrhea treatment market and is expected to continue dominating the market in the coming years. Much of this anticipated demand for dysmenorrhea treatment can be attributed to the increasing number of patients suffering from menstrual disorders. For example, an online survey of 30,000 women in Canada aged 18 to 49 was conducted from December 2018 through January 2019. Among these surveyed women, 70.3% of respondents experienced menstrual pelvic pain or cramping, while non-menstrual pelvic pain was experienced by 49.5% of the respondents.


Europe:


The dysmenorrhea treatment market in Europe accounted for the second-largest revenue generating region globally. The clinical trials focused on relieving pain associated with dysmenorrhea are expected to increase the number of available effective treatment options during the forecast period. For instance, Myovant Sciences (UK) and Pfizer (US) released one-year data from the phase 3 SPIRIT Extension Study. Based on this clinical trial, 84.8% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) at a one-year period.


Asia-Pacific:


Asia-Pacific is one of the fastest-growing dysmenorrhea treatment regional market during the review period. The factors primarily responsible for the growth of the dysmenorrhea treatment market in the region are the increasing population and the rise in the level of awareness about the condition created by government. For instance, the Women and Child Welfare Department, Pune Zilla Parishad, India, launched a novel initiative during March 2021 for menstruating women by launching Sakhi Cells, a kiosk for rest, provision of essential medicines, and other products.


Middle East & Africa:


The Middle East & Africa dysmenorrhea treatment market accounted for the least market share and is expected to witness significant growth in the coming years during the forecast period. Much of these factors can be attributed to the growing awareness created by research studies and the severity of outcomes of undiagnosed cases.


Competitive Landscape


The global dysmenorrhea treatment market is distinguished by the presence of numerous global, regional, and local players catering to technological advancements, government investment in academics and life sciences, and growth in generics and CROs. The increasing prevalence of dysmenorrhea among adolescent girls and increasing cases of menstrual cramps due to genetic disorders are making the dysmenorrhea treatment market more lucrative. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs.


In February 2021, Reckitt Benckiser Group plc. acquired Biofreeze brand from Performance Health (US). The acquisition will accelerate the growth of Reckitt's pain relievers management and diversify its product offerings in the dysmenorrhea treatment segment. In September 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women's healthcare. This acquisition will help the company deliver a new treatment option that could have a meaningful impact on women's lives.


List of Key Companies Covered in this report:



  • Johnson & Johnson (US)

  • GlaxoSmithKline PLC (UK)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Bayer AG (Germany)

  • Focus Consumer Healthcare, LLC (US)

  • Novartis AG (Switzerland)

  • Pfizer, Inc. (US)

  • Reckitt Benckiser Group plc. (UK)

  • Sanofi S.A. (France)

  • Viatris Inc. (US)


Recent Developments



  • In February 2021, Reckitt Benckiser Group plc. acquired Biofreeze brand from Performance Health (US). The acquisition will accelerate Reckitt’s pain relievers management and diversify its product offerings in the dysmenorrhea treatment segment.

  • In September 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd to expand its drug development pipeline in women's healthcare. This acquisition will help the company deliver a new treatment option that could have a meaningful impact on women's lives. 


Report Overview:


The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.


Scope of the Report & Segmentation


Global Dysmenorrhea Treatment Market, by Product Type



  • Primary Dysmenorrhea

  • Secondary Dysmenorrhea


Global Dysmenorrhea treatment market, by Type of Treatment



  • Pain Relievers

  • Hormonal Therapy

  • Surgery

  • Others


Global Dysmenorrhea treatment market, by End User



  • Hospitals & Clinics

  • Research Centres

  • Other


Global Dysmenorrhea treatment market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Europe



    • Eastern Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa





Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 6,312.88 Million
  CAGR   7.9%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Type of Treatment, End User, and Region
  Geographies Covered   Americas, Europe, Asia-Pacific, Middle East & Africa
  Key Vendors   β€’ Johnson & Johnson (US) β€’ GlaxoSmithKline PLC (UK) β€’ F. Hoffmann-La Roche Ltd (Switzerland) β€’ Bayer AG (Germany) β€’ Focus Consumer Healthcare, LLC (US) β€’ Novartis AG (Switzerland) β€’ Pfizer, Inc. (US) β€’ Reckitt Benckiser Group plc. (UK) β€’ Sanofi S.A. (France) β€’ Viatris Inc. (US)
  Key Market Opportunities   β€’ The emergence of nonsteroidal anti-inflammatory drugs for dysmenorrhea treatment
  Key Market Drivers   β€’ Increasing prevalence of dysmenorrhea among adolescent girls β€’ Increasing cases of menstrual cramps due to genetic disorders


Speak to Analyst Ask for Customization